New cancer treatment "from its roots"

The US Food and Drug Administration (FDA) has adopted a new cancer treatment that focuses on genetic biogenesis to try to completely overcome it.

According to US Today, the US FDA has adopted Vitrakvi, the trade name for larotrectinib, a novel method of developing cancer drugs for the treatment of tissue, that is, they are not topical medications for treating a drug. member, like the colon or the breast, But treat the disease by its roots.

The drug was developed to treat solid tumors wherever they develop in the body, according to the newspaper, which indicates that the cost of treatment "will not be cheap", given the scarcity of the therapeutic thrust .

The cancer test costs thousands of dollars and the treatment can cost hundreds of thousands of dollars.

Although it is not clear how much the patient will pay for treatment, the manufacturer insists that any cancer patient will not be spared.

This medicine can save the lives of patients who have no alternative.

Dr. Michael Weiner, pediatric oncologist and vice president of pediatric medicine at Columbia University, said that the genetic approach was the "new horizon" of cancer treatment.

"We are moving away from the era of chemotherapy to direct us to immunotherapy, which includes the ability to detect and target mutations."

According to the newspaper, the first results of the drug "Vitrakvi" are encouraging, because the treatment answered 75% of the recipients of the drug, while 73% of responses lasted at least six months.

"The response of about 40% of subjects took a year or more," the FDA said.